BioMarin Pharmaceutical and Idorsia Pharmaceuticals side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | BioMarin Pharmaceutical | Idorsia Pharmaceuticals |
|---|---|---|
| Phase 1 | BioMarin Pharmaceutical: 1 of its 8 programs at phase 1
| 00% |
| Phase 2 | BioMarin Pharmaceutical: 1 of its 8 programs at phase 2
| Idorsia Pharmaceuticals: 1 of its 4 programs at phase 2
|
| Phase 3 | BioMarin Pharmaceutical: 4 of its 8 programs at phase 3
| Idorsia Pharmaceuticals: 2 of its 4 programs at phase 3
|
| Approved, new studies | BioMarin Pharmaceutical: 2 of its 8 programs at approved, new studies
| Idorsia Pharmaceuticals: 1 of its 4 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioMarin Pharmaceutical3 readouts · 2 phase 3 | · | BioMarin Pharmaceutical, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | · | BioMarin Pharmaceutical, Apr ’27: 1 program whose next study reaches primary completion
| · | · | · | · | BioMarin Pharmaceutical, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · |
| Idorsia Pharmaceuticals1 readouts · 0 phase 3 | · | · | · | · | · | · | · | Idorsia Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion
| · | · | · | · |
Changed in the last 90 days
Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
BioMarin Pharmaceutical
New programs 0
None
Reached a new phase 0
None
Study stopped 4
- vosoritidephase 2 · terminated Nov 13“BioMarin has decided to discontinue the study after assessing a number of factors, including study feasibil…” · NCT06668805
- efmirenpase alfaphase 2 · terminated Oct 19 · none of its studies left running“The study was terminated by the sponsor prior to planned completion based on a review of the data across in…” · NCT06462547
- efmirenpase alfaphase 1 · terminated Oct 15 · none of its studies left running“The study was terminated by the sponsor prior to planned completion based on a review of the data across in…” · NCT05734196
- efmirenpase alfaphase 3 · terminated Oct 1 · none of its studies left running“The study was terminated by the sponsor prior to planned completion based on a review of the data across in…” · NCT06046820
Primary completion later 0
None
Idorsia Pharmaceuticals
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Where they overlap
Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.
| Condition | BioMarin Pharmaceutical | Idorsia Pharmaceuticals |
|---|---|---|
| Fabry Diseaseboth · compare here | BioMarin Pharmaceutical in Fabry Disease: 1 program
Their studies: BioMarin Pharmaceutical’s studies of Fabry Disease in search | Idorsia Pharmaceuticals in Fabry Disease: 1 program
Their studies: Idorsia Pharmaceuticals’ studies of Fabry Disease in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
| Target | BioMarin Pharmaceutical | Idorsia Pharmaceuticals |
|---|---|---|
| GLA | migalastatrule | migalastatrule |
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.